CoChat
Sign Up
Cited by 223Cannabis and Cannabinoid ResearchAutism Spectrum Disorder ResearchChild Nutrition and Feeding Issues

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Cannabinoid treatment for autism: a proof-of-concept randomized trial

Open access
Aran, Adi, Harel, Moria, Cassuto, Hanoch, Polyansky, Lola, Schnapp, Aviad, Wattad, Nadia, Shmueli, Dorit, Golan, Daphna, Castellanos, F. Xavier·2021·Molecular Autism
DOI 10.1186/s13229-021-00420-2PMC PMC7860205
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5-21 years) with ASD. METHODS: We tested (1) BOL-DP-O-01-W, a whole-plant cannabis extract containing cannabidiol and Δ9-tetrahydrocannabinol at a 20:1 ratio and (2) BOL-DP-O-01, purified cannabidiol and Δ9-tetrahydrocannabinol at the same ratio. Participants (N = 150) received either placebo or cannabinoids for 12-weeks (testing efficacy) followed by a 4-week washout and predetermined cross-over for another 12 weeks to further assess tolerability. Registered primary efficacy outcome measures were improvement in behavioral problems (differences between whole-plant extract and placebo) on the Home Situation Questionnaire-ASD (HSQ-ASD) and the Clinical Global Impression-Improvement scale with disruptive behavior anchor points (CGI-I). Secondary measures were Social Responsiveness Scale (SRS-2) and Autism Parenting Stress Index (APSI). RESULTS: Changes in Total Scores of HSQ-ASD (primary-outcome) and APSI (secondary-outcome) did not differ among groups. Disruptive behavior on the CGI-I (co-primary outcome) was either much or very much improved in 49% on whole-plant extract (n = 45) versus 21% on placebo (n = 47; p = 0.005). Median SRS Total Score (secondary-outcome) improved by 14.9 on whole-plant extract (n = 34) versus 3.6 points after placebo (n = 36); p = 0.009). There were no treatment-related serious adverse events. Common adverse events included somnolence and decreased appetite, reported for 28% and 25% on whole-plant extract, respectively (n = 95); 23% and 21% on pure-cannabinoids (n = 93), and 8% and 15% on placebo (n = 94). Limitations Lack of pharmacokinetic data and a wide range of ages and functional levels among participants warrant caution when interpreting the results. CONCLUSIONS: This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended. Trial registration ClinicalTrials.gov: NCT02956226. Registered 06 November 2016, https://clinicaltrials.gov/ct2/show/NCT02956226.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13229-021-00420-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design
Fig. 1 Study designCC BY · PubMed Central
Fig. 2 Trial profile: screening, randomization and treatment periods
Fig. 2 Trial profile: screening, randomization and treatment periodsCC BY · PubMed Central
Fig. 3 Participants (%) whose behavioral problems either much improved or very much improved on the CGI-I scale following treatment. Response to 12-week treatment using the Clinical Global Impression-Improvement (CGI-I). Positive response in this scale is defined as a rating of ‘much improved' or 'very much improved' [34]. Outcome was analyzed using Likelihood ratio chi-square test. P value is unadjusted. *Remains significant after Bonferroni-correction for multiple comparisons
Fig. 3 Participants (%) whose behavioral problems either much improved or very much improved on the CGI-I scale following treatment. Response to 12-week treatment using the Clinical Global Impression-Improvement (CGI-I). Positive response in this scale is defined as a rating of ‘much improved' or 'very much improved' [34]. Outcome was analyzed using Likelihood ratio chi-square test. P value is unadjusted. *Remains significant after Bonferroni-correction for multiple comparisonsCC BY · PubMed Central
Fig. 4 Impact of cannabinoid treatment on BMI. Change in BMI during 12-week treatment with either cannabinoids or placebo. a Whole-plant extract versus pure cannabinoids; b Cannabinoid treatment (either whole-plant extract or pure cannabinoids) versus placebo; c Distribution of data, bars represent 10%, 25%, Median, 75% and 90%, differences between placebo and cannabinoids were analyzed using median test; d, e Change in BMI as function of baseline level, stratified by treatment (cannabinoids or placebo) and treatment period (d first period, e second period). Correlations were analyzed using linear regression
Fig. 4 Impact of cannabinoid treatment on BMI. Change in BMI during 12-week treatment with either cannabinoids or placebo. a Whole-plant extract versus pure cannabinoids; b Cannabinoid treatment (either whole-plant extract or pure cannabinoids) versus placebo; c Distribution of data, bars represent 10%, 25%, Median, 75% and 90%, differences between placebo and cannabinoids were analyzed using median test; d, e Change in BMI as function of baseline level, stratified by treatment (cannabinoids or placebo) and treatment period (d first period, e second period). Correlations were analyzed using linear regressionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Sparrow SS, Balla DA, Cicchetti DV. Vineland adaptive behavior scales: survey form manual. Circle Pines: American Guidance Service; 1984.
  2. Constantino JN, Gruber CP. The social responsiveness scale (SRS) (Manual). Los Angeles: Western Psychological Services; 2005.

Cited by

Sorted by citations

Items 101–200 of 223

Related

See all

Metadata

Authors
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X.
Affiliations
  • Shaare Zedek Medical Center (IL)
  • Clalit Health Services (IL)
  • Maccabi Healthcare Services (IL)
  • New York University (US)
Corresponding author
Aran, Adi
ORCID
Venue
Molecular Autism
Publisher
Springer Science and Business Media LLC
Published
2021-02-03
Volume
12
Issue
1
Pages
6-6
ISSN
2040-2392 (ISSN-L)
DOI
10.1186/s13229-021-00420-2
PMC
PMC7860205
OpenAlex
W3126959679
Cited by
223
References
43
Citations by year
2026: 21 · 2025: 63 · 2024: 53 · 2023: 30 · 2022: 42 · 2021: 14
FWCI
20.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Autism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • BOL Pharma, Revadim, Israel
  • National Institute for Psychobiology in Israel, Hebrew University of Jerusalem (203-17-18)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
Keywords
autism spectrum disorder, cannabinoids, cannabidiol, tetrahydrocannabinol, disruptive behavior, social responsiveness, parental stress, treatment tolerability, adverse events, sleepiness, appetite suppression, crossover design, Social Responsiveness Scale
MeSH terms
Autism Spectrum Disorder, Adolescent, Adult, Autistic Disorder, Cannabinoids, Child, Child, Preschool, Female, Humans, Male, Social Behavior, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review